Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* FORD KATHLEEN						2. Issuer Name and Ticker or Trading Symbol Kura Oncology, Inc. [ KURA ]									all appli Directo	applicable)		g Person(s) to Issuer 10% Owner Other (spec	
	RA ONCO	LOGY, INC.	(Middle)	,		3. Date of Earliest Transaction (Month/Day/Year) 12/15/2020							Λ	below) below)  Chief Operating Officer					
12/30 H	IGH BLUF	F DRIVE, SUIT	E 400		_ 4.1	f Amer	dmer	nt, Date	of Orig	ginal F	iled (Month/D	ay/Year)			vidual or	Joint/Group	Filing	(Check Ap	plicable
(Street) SAN DII	EGO C.	A	92130							. , ,					e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)																
		Tab	le I - I	Non-Deriv	/ative	e Sec	uriti	ies A	cquir	ed, D	isposed o	of, or B	enefic	cially	Owned	t			
Da		Date E. (Month/Day/Year) if		Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			i 5)	Securiti Benefic Owned	5. Amount of Securities Beneficially Owned Following		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	ode V Amount		(A) or (D)	Price	Price		Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common Stock 12/15/20			020	20			M <sup>(1)</sup>		6,250	Α	\$19	.43	6,	6,250		D			
Common	Common Stock 12/15/20			020	0		S <sup>(1)</sup>		6,250	D	\$40.6	40.6049 <sup>(2)</sup>		0		D			
Common	Stock			12/15/2	020			M <sup>(1)</sup>		3,125	A	\$19	\$19.43		3,125		D		
Common	Stock			12/15/2	020				S <sup>(1)</sup>		3,125	D	\$40.6	035(3)	(3) 0 D				
		Т	able						•	,	sposed of , converti	,		•	wned				
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  Security  3. Transaction Date Execution Date (Month/Day/Year) if any (Month/Day/Year)		tion Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/		ate	7. Title and Amount of Securities Underlying Derivative Sect (Instr. 3 and 4)		rity Discontinuo	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amor or Numl of Share	ber					
Option to purchase common	\$19.43	12/15/2020			M <sup>(1)</sup>			9,375	(4	4)	08/08/2029	Commo	9,37	75	\$0.00	221,87	5	D	

## **Explanation of Responses:**

- $1. \ The \ transactions \ were \ effected \ pursuant \ to \ a \ Rule \ 10b5-1 \ trading \ plan \ adopted \ by \ the \ reporting \ person \ on \ May \ 13, \ 2020.$
- 2. This transaction was executed in multiple trades at prices ranging from \$40.07 to \$41.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 3. This transaction was executed in multiple trades at prices ranging from \$40.06 to \$41.315. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 4. This option vests in 48 equal monthly installments commencing on August 9, 2019.

## Remarks:

James Basta, Attorney-in-fact for Kathleen Ford

12/16/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.